A potent anti-cancer treatment co-developed and trialled in Melbourne has been granted approval for use in patients by the powerful US Food and Drug Administration (FDA). The announcement recognises that the drug, venetoclax, is a successful new therapy…
Walter and Eliza Hall Institute researchers have revealed for the first time the three-dimensional molecular ‘map’ of a protein that has been pinpointed as a driver of many types of cancers. The unprecedented view of the protein doublecortin…
Walter and Eliza Hall Institute researchers have revealed for the first time the three-dimensional molecular ‘map’ of a protein that has been pinpointed as a driver of many types of cancers. More than one in 10 stomach cancers…
Victoria has provided $50 million in funding towards establishing a National Proton Beam Therapy Centre for the treatment of cancer in Melbourne. Minister for Health, Jill Hennessy, made the announcement while touring the construction of University College London…
12th August, 2016 A form of regulated cell death known as necroptosis – and its role in health and disease – is the topic of new research by Walter and Eliza Hall Institute scientists. An international team of…
BioMelbourne Network, on behalf of the State Government of Victoria, is leading a major Medtech Mission to the United States including AdvaMed 2016 – the largest annual medical technology conference on the US calendar. There are still limited…
US based Medtronic representative, Dr Huzefa Neemuchwala, will be in Melbourne this month. BioMelbourne Network member organisations are invited to meet with Dr Neemuchwala. Interested organisations, please contact Dr Krystal Evans on 9667 6161 Dr Huzefa Neemuchwala, PhD MBA,…
THIS SEMINAR IS FULLY BOOKED The BioMelbourne Network and Biomedical Research Victoria present international guest speaker, Dr Gerald Chan, CEO, Morningside, USA Free Seminar: The Role of Universities in the Innovation Ecosystem With Australia’s changing economy, the role of universities…
26th July, 2016 Melbourne, Australia, July 26 2016 – Opthea Limited (ASX:OPT) • Phase 1 dose escalation study met primary objective demonstrating OPT-302 safety and tolerability as monotherapy and in combination with standard of care Lucentis® • Changes…
The National Stem Cell Foundation of Australia (based in Victoria) supports stem cell science and educates the community about the potential and dangers of stem cell therapies.The winners of the 2016 Metcalf Prizes for Stem Cell Research were…
26th July, 2016 MTP Connect chief executive officer Sue MacLeman says her Federal Government funded initiative aim is “to drive competitiveness and productivity of the sector”. Ms MacLeman told Biotech Daily that the launch of a 10-year plan…
26th July, 2016 A BREAKTHROUGH discovery has opened up a potential new drug to stop lung cancer and emphysema as well as detecting the killer diseases much sooner. Researchers from Melbourne’s Hudson Institute of Medical Science have identified…